Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma

Clinical Cancer Research

Volumn 23, Issue 17, 2017, Pages 5187-5201

  Orillion, Ashley ^a,b   Hashimoto, Ayumi ^c   Damayanti, Nur ^a   Shen, Li ^d   Adelaiye Ogala, Remi ^a,b   Arisa, Sreevani ^a   Chintala, Sreenivasulu ^a   Ordentlich, Peter ^e   Kao, Chingai ^f   Elzey, Bennett ^f,g   Gabrilovich, Dmitry ^c   Pili, Roberto ^a,f  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c WISTAR INSTITUTE   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e Syndax   (United States)

^f INDIANA UNIVERSITY   (United States)

^g Purdue University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTINOSTAT; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN INHIBITOR; BENZAMIDE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; PDCD1 PROTEIN, MOUSE; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTINYLATION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; IMMUNE RESPONSE; IMMUNOPRECIPITATION; IMMUNOREGULATION; IMMUNOSURVEILLANCE; LUNG CARCINOMA; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RENAL CELL CARCINOMA; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROCEDURES;

ANIMALS; BENZAMIDES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; DISEASE MODELS, ANIMAL; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MICE; MYELOID-DERIVED SUPPRESSOR CELLS; PROGRAMMED CELL DEATH 1 RECEPTOR; PYRIDINES; TUMOR MICROENVIRONMENT;

EID: 85029426178     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-0741     Document Type: Article

References (37)

1. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
3. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13.
4. Quinn DI, Lara PN Jr. Renal-cell cancer-targeting an immune checkpoint or multiple kinases. N Engl J Med 2015;373:1872-4.
5. Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One 2012;7:e30815.
6. Shen L, Orillion A, Pili R. Histone deacetylase inhibitors as immunomo-dulators in cancer therapeutics. Epigenomics 2016;8:415-28.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
8. Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy: a double edged sword? Oncotarget 2014;5:6558-72.
9. Draghiciu O, Lubbers J, Nijman HW, Daemen T. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology 2015;4:e954829.
10. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cellsasregulators of the immune system. Nat Rev Immunol 2009;9:162-74.
11. Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol 2013;14:211-20.
12. Rosborough BR, Castellaneta A, Natarajan S, Thomson AW, Turnquist HR. Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J Leukoc Biol 2012;91:701-9.
13. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci USA 2014; 111:11774-9.
14. James BR, Anderson KG, Brincks EL, Kucaba TA, Norian LA, Masopust D, et al. CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. Cancer Immunol Immun-other 2014;63:1213-27.
15. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, et al. Immunogenicity of murine solid tumor models as a defining featureofinvivo behavior and responsetoimmunotherapy.JImmunother 2013;36:477-89.
16. Sgambato A, Casaluce F, Sacco PC, Palazzolo G, Maione P, Rossi A, et al. Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): a review on toxicity profile and its management. Curr Drug Saf 2016;11:62-8.
17. Kwon H-S, Lim HW, Wu J, Schnoelzer M, Verdin E, Ott M. Three novel acetylation sites in the Foxp3 transcription factor regulate the suppressive activity of regulatory T cells. J Immunol 2012;188:2712-21.
18. Song X, Li B, Xiao Y, Chen C, Wang Q, Liu Y, et al. Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function. Cell Rep 2012;1:665-75.
19. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
20. Hadrup S, Donia M, Thor Straten P. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron 2013; 6:123-33.
21. Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 2012;91:167-81.
22. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016;7:12150.
23. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 2015; 125:3356-64.
24. Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 2011;121:4015-29.
25. Lu T, Gabrilovich DI. Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenviron-ment. Clin Cancer Res 2012;18:4877-82.
26. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cellsinthe tumor microenvironment. Trends Immunol 2016;37:208-20.
27. Liu F, Li X, Lu C, Bai A, Bielawski J, Bielawska A, et al. Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells. Oncotarget 2016;7:83907-25.
28. Lu C, Redd PS, Lee JR, Savage N, Liu K. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. Onco Immunology 2016;5:e1247135.
29. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181: 5791-802.
30. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006;4:48.
31. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 2007;13(15 Pt 1):4538-46.
32. Tomita Y, Lee MJ, Lee S, Tomita S, Chumsri S, Cruickshank S, et al. The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat. Oncoimmunology 2016;5: e1219008.
33. Zheng H, Zhao W, Yan C, Watson CC, Massengill M, Xie M, et al. HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin Cancer Res 2016; 22:4119-32.
34. Cantley MD, Fairlie DP, Bartold PM, Marino V, Gupta PK, Haynes DR. Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis. Rheumatology (Oxford) 2015;54:1713-23.
35. Cantley MD, Haynes DR. Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs. Inflammopharmacology 2013;21:301-7.
36. Beury DW, Carter KA, Nelson C, Sinha P, Hanson E, Nyandjo M, et al. Myeloid-derived suppressor cell survival and function are regulated by the transcription factor Nrf2. J Immunol 2016;196:3470-8.
37. Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, et al. Immunomodulation by HDAC inhibition: results from a phase II study with entinostat and high-dose interleukin 2in renal cell carcinoma patients (CTEP#7870). Presented at: 2016 Genitourinary Cancers Symposium; January 7-9, 2016; San Francisco, CA. Abstract 500.